Primecap Management Co. CA Purchases 11,000 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Primecap Management Co. CA boosted its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT) by 5.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 233,015 shares of the company’s stock after purchasing an additional 11,000 shares during the period. Primecap Management Co. CA owned about 0.52% of Health Catalyst worth $12,935,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. SG Americas Securities LLC raised its stake in shares of Health Catalyst by 222.1% in the first quarter. SG Americas Securities LLC now owns 64,788 shares of the company’s stock worth $3,030,000 after acquiring an additional 44,672 shares during the last quarter. Voloridge Investment Management LLC bought a new position in shares of Health Catalyst in the first quarter worth about $703,000. Vontobel Holding Ltd. raised its stake in shares of Health Catalyst by 72.5% in the first quarter. Vontobel Holding Ltd. now owns 37,017 shares of the company’s stock worth $1,731,000 after acquiring an additional 15,557 shares during the last quarter. Mckinley Capital Management LLC Delaware raised its stake in shares of Health Catalyst by 34.5% in the second quarter. Mckinley Capital Management LLC Delaware now owns 87,310 shares of the company’s stock worth $4,847,000 after acquiring an additional 22,390 shares during the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Health Catalyst by 0.7% in the first quarter. Janus Henderson Group PLC now owns 1,447,832 shares of the company’s stock worth $67,715,000 after acquiring an additional 10,138 shares during the last quarter.

Shares of NASDAQ HCAT opened at $55.37 on Friday. The stock has a market cap of $2.58 billion, a P/E ratio of -17.63 and a beta of 0.63. The firm has a 50 day moving average price of $54.64 and a 200 day moving average price of $53.04. Health Catalyst, Inc. has a 52-week low of $31.65 and a 52-week high of $59.50.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Thursday, August 5th. The company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.02. The company had revenue of $59.63 million during the quarter, compared to analysts’ expectations of $56.68 million. Health Catalyst had a negative net margin of 62.31% and a negative return on equity of 24.68%. On average, analysts forecast that Health Catalyst, Inc. will post -1.83 EPS for the current year.

In related news, President James Patrick Jr. Nelli sold 29,380 shares of the stock in a transaction on Monday, September 13th. The shares were sold at an average price of $54.77, for a total transaction of $1,609,142.60. Following the completion of the transaction, the president now owns 148,666 shares in the company, valued at $8,142,436.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Jason Alger sold 652 shares of the stock in a transaction on Friday, September 3rd. The stock was sold at an average price of $54.23, for a total transaction of $35,357.96. Following the transaction, the chief accounting officer now owns 15,312 shares of the company’s stock, valued at approximately $830,369.76. The disclosure for this sale can be found here. Insiders sold 149,451 shares of company stock valued at $8,202,064 in the last quarter. Corporate insiders own 2.00% of the company’s stock.

A number of equities research analysts recently weighed in on the stock. Canaccord Genuity boosted their price target on shares of Health Catalyst from $60.00 to $64.00 and gave the stock a “buy” rating in a research note on Friday, August 6th. Royal Bank of Canada boosted their price target on shares of Health Catalyst from $60.00 to $66.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 10th. Raymond James boosted their price target on shares of Health Catalyst from $66.00 to $70.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, August 10th. SVB Leerink boosted their price target on shares of Health Catalyst from $62.00 to $64.00 and gave the stock an “outperform” rating in a research note on Friday, August 6th. Finally, Piper Sandler boosted their price target on shares of Health Catalyst from $57.00 to $66.00 and gave the stock an “overweight” rating in a research note on Friday, August 6th. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst presently has a consensus rating of “Buy” and a consensus target price of $60.00.

Health Catalyst Company Profile

Health Catalyst, Inc engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers.

Read More: Euro STOXX 50 Index

Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCAT).

Institutional Ownership by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.